Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging (SMArT–HS)

Grants and Contracts Details


prevalent, high-morbidity disease with symptoms that mimic Alzheimer’s disease (AD). The primary aims are to test the safety and efficacy of nicorandil for HS-Aging, based on our prior work elucidating a pharmacologically targetable mechanism for this prevalent cause of cognitive decline and dementia in the aging population as described below. Nicorandil is a vasorelaxant drug, used clinically to treat chronic heart failure in the elderly population, which has not been tested in humans for the purpose of preventing or treating dementia. “AD mimics” (diseases with pathologies other than AD-type plaques and tangles but with similar symptoms) are increasingly appreciated to be important causes of dementia. HS-Aging is a major subtype of “AD and related dementia” (ADRD), affecting ~10-25% of all persons beyond age 85 years, strongly associated with dementia, and with a very large public health impact. Primary specific aims follow: Specific Aim #1: Evaluate safety and neurodegenerative biomarkers linked to HS-aging pathology both cross-sectionally and longitudinally in nicorandil vs. placebo treated subjects by: a. Conducting a double-blind, randomized, placebo-controlled, single-center, parallel arms design clinical trial of nicorandil in 62 participants (both sexes, >80 years of age, CDR
Effective start/end date2/1/1911/30/25


  • National Institute on Aging: $2,853,648.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.